Exactitude Consultancy
Home Report Store Categories Primary Research Consulting Services Blog Contact us About Us Terms & Conditions Privacy Policy

Particle Therapy Market

Nov 2023

Base Year Value ()

x.x %
x.x %

CAGR ()

x.x %
x.x %

Forecast Year Value ()

x.x %
x.x %

Historical Data Period

Largest Region

Forecast Period

Particle Therapy Market By Type (Proton Therapy, Heavy Ion Therapy), By Product (Synchrotron, Cyclotrons), By Cancer Type (Prostate Cancer, Lung Cancer, Pediatric Cancer, Breast Cancer), By End User (Hospitals, Research Centers), And Region, Global Trends and Forecast From 2023 to 2030.

Instant access to hundreds of data points and trends

  • Market estimates from 2014-2029
  • Competitive analysis, industry segmentation, financial benchmarks
  • Incorporates SWOT, Porter's Five Forces and risk management frameworks
  • PDF report or online database with Word, Excel and PowerPoint export options
  • 100% money back guarantee

Particle Therapy Market Overview


The particle therapy market is expected to grow at 8% CAGR from 2023 to 2030. It is expected to reach above USD 1432.30 Million by 2030 from USD 835.73 Million in 2023.

Particle therapy is a type of external beam radiotherapy that uses beams of high-energy protons, positive ions, or neutrons to treat cancer. It is a cutting-edge technique that delivers radiation to cancerous cells while sparing the surrounding healthy tissues. This precision in targeting cancer cells makes particle therapy an effective treatment option for certain types of cancers, including those that are resistant to conventional radiation therapy. The global particle therapy market is witnessing significant growth due to various factors. The rising incidence of cancer worldwide is one of the primary drivers of this market. According to the World Health Organization (WHO), cancer is the second leading cause of death globally, accounting for an estimated 9.6 million deaths in 2018. The increasing prevalence of cancer has led to a rise in demand for advanced and effective cancer treatments, such as particle therapy. Another significant driver of the particle therapy market is the increasing use of particle therapy in clinical trials.

[caption id="attachment_30535" align="aligncenter" width="1920"]Particle Therapy Market | Exactitude Consultancy
Particle Therapy Market | Exactitude Consultancy
[/caption]

Moreover, the rising number of particle therapy centers worldwide is contributing to the growth of the particle therapy market. Governments and healthcare organizations are investing in building new particle therapy centers to meet the increasing demand for this advanced cancer treatment. This is particularly true in developed countries where there is a higher prevalence of cancer. However, despite the significant growth opportunities, the particle therapy market is facing some challenges. Unfavorable reimbursement policies and limited insurance coverage for particle therapy are hindering market growth. Additionally, the increasing affordability and accessibility of alternative treatments, such as conventional radiation therapy, may also restrain the growth of the particle therapy market. However, challenges such as unfavorable reimbursement policies, limited insurance coverage, and increasing affordability and accessibility of alternative treatments may restrain market growth.

The construction and installation of new particle therapy centers have been hindered by the pandemic, with progress being slowed due to lockdowns, supply chain disruptions, and other challenges related to the pandemic. Cancer patients have postponed or delayed their treatments due to concerns about contracting COVID-19 or restrictions on non-essential medical procedures, resulting in a decrease in patient volumes for particle therapy treatments and other cancer therapies.
























































ATTRIBUTE DETAILS
Study period 2020-2030
Base year 2022
Estimated year 2023
Forecasted year 2023-2030
Historical period 2019-2021
Unit Value (USD Million)
Segmentation By Type, By Product, By Cancer type, By End user, By Region
By Type

 


  • Proton Therapy

  • Heavy Ion Therapy


By Product

 


  • Synchrotron

  • Cyclotrons


By Cancer type

 


By End user

 


  • Hospitals

  • Research centers


By Region

  • North America

  • Asia Pacific

  • Europe

  • South America

  • Middle East Asia & Africa



Frequently Asked Questions

What is the worth of particle therapy market?

The particle therapy market is expected to grow at 8% CAGR from 2023 to 2030. It is expected to reach above USD 1432.30 Million by 2030 from USD 835.73 Million in 2023.

What are some of the market's driving forces?

The particle therapy market would be driven by factors like rising cases of cancer, an increasing number of particle therapy center, low risk of treatment, and potential retreatment opportunity can trigger better market growth.

Which are the top companies to hold the market share in particle therapy market?

IBA Worldwide, Mevion Medical Systems, Varian Medical Systems, Sumitomo Heavy Industries Ltd, Hitachi Ltd, Toshiba Medical Systems Corp., Provision Healthcare LLC., Danfysik A/S, Optivus Proton Therapy, ProTom International Inc, Advanced Oncology plc, Ion Beam Application SA, Elekta AB are the major particle therapy market players.

Which is the largest regional market for particle therapy market?

The region's largest share is in North America. Type that is manufactured in nations like US and Canada that perform similarly and are inexpensively accessible to the general public have led to the increasing appeal. Also, the key players such as Analog Devices, Inc., Belden Inc. play important roles.

Particle therapy Market Segment Analysis

The particle therapy market is segmented based on type, product, cancer type, end user, and region. Based on type, the particle therapy market segmentation has been divided into proton therapy, heavy ion therapy. Due to the many benefits of this therapy, the proton therapy segment had the greatest revenue share in 2022. Proton beam therapy, commonly referred to as particle therapy, is a type of radiation therapy that targets cancer cells with pinpoint accuracy. Proton treatment appears to be safer, painless, noninvasive, and more helpful than traditional radiation therapy since it can provide a large dose to a very targeted location. The American Society of Clinical Oncology (ASCO) claims that proton treatment gives the tumor a higher dose of radiation while delivering up to 60% less radiation to the surrounding healthy tissue. The precise timing and position of the proton's energy release can be chosen by the doctor in this beam therapy. This allows for maximum damage to cancer cells and little damage to adjacent tissue. [caption id="attachment_30539" align="aligncenter" width="1920"]Particle Therapy Market | Exactitude Consultancy
Particle Therapy Market | Exactitude Consultancy
[/caption] The particle therapy market has been segmented into synchrotron, cyclotrons. During the forecast period, the synchrotron segment is anticipated to have the fastest revenue growth rate. Protons are accelerated in a synchrotron during this proton therapy, also known as particle therapy. During the forecast period, the synchrotron segment is anticipated to have the fastest revenue growth rate. Protons are accelerated in a synchrotron during this proton therapy, also known as particle therapy. [caption id="attachment_30540" align="aligncenter" width="1920"]Particle Therapy Market | Exactitude Consultancy
Particle Therapy Market | Exactitude Consultancy
[/caption] The particle therapy market is segmented into categories based on cancer type, prostate cancer, lung cancer, breast cancer. In 2022, the market segment that handled lung cancer had the biggest revenue share. Lung cancer is the most frequent cancer kind that results in mortality, according to the Centers for Disease Control and Prevention (CDC). Smoking cigarettes and other tobacco products, including pipes or cigars, is the main risk factor for developing this type of cancer. Other risk factors for lung cancer include smoking, being exposed to asbestos or radon at work or home, and having a family history of the disease. Smokers have a 15–30 times higher risk of getting lung cancer than nonsmokers, which is what is causing the segment's revenue increase. During the forecast period, the breast cancer segment is anticipated to have the fastest revenue CAGR. Breast cancer is the second most common cancer in women overall and the most prevalent in Hispanic women, according to the CDC. It has been demonstrated that radiation therapy, such as post-lumpectomy, improves survival and lowers breast cancer recurrence. Breast cancer patients who undergo a lumpectomy or mastectomy also undergo radiation therapy to eradicate any cancer cells that may have survived. The particle therapy market is segmented into the hospitals, research centers. As they frequently have the infrastructure and resources to provide particle therapy to cancer patients, hospitals are the primary end users of particle therapy devices and equipment. However, the market for cancer research organizations and ambulatory surgical centers is also expanding. [caption id="attachment_30541" align="aligncenter" width="1920"]Particle Therapy Market | Exactitude Consultancy
Particle Therapy Market | Exactitude Consultancy
[/caption]

Particle Therapy Market Players

IBA Worldwide, Mevion Medical Systems, Varian Medical Systems, Sumitomo Heavy Industries Ltd, Hitachi Ltd, Toshiba Medical Systems Corp., Provision Healthcare LLC., Danfysik A/S, Optivus Proton Therapy, ProTom International Inc, Advanced Oncology plc, Ion Beam Application SA, Elekta AB are the major particle therapy market players. Recent News: 27 July, 2022: UW Health selected Hitachi, Ltd. To provide the infrastructure to support proton therapy at UW Health Eastpark Medical Center. Hitachi will provide equipment and technology to support UW Health’s traditional proton therapy room equipped with spot scanning irradiation technology. 10 January, 2023: IBA announced that it signed a contract with the H. Lee Moffitt Cancer Center and Research Institute Hospital for installation of its ProteusONE compact proton therapy system.

Who Should Buy? Or Key stakeholders

  • Medical Devices Manufacturers
  • Medical Devices Product Distributors and Suppliers
  • Healthcare Providers
  • Contract Manufacturing Organizations
  • Government & Regional Agencies
  • Research centers Research Institute
  • Investors
  • Regulatory Authorities

Particle Therapy Market Regional Analysis

The Particle therapy market by region includes North America, Asia-Pacific (APAC), Europe, South America, and Middle East & Africa (MEA).
  • North America: includes the US, Canada, Mexico
  • Asia Pacific: includes China, Japan, South Korea, India, Australia, ASEAN, and Rest of APAC
  • Europe: includes UK, Germany, France, Italy, Spain, Russia, and Rest of Europe
  • South America: includes Brazil, Argentina, and Rest of South America
  • Middle East & Africa: includes Turkey, UAE, Saudi Arabia, South Africa, and Rest of MEA
[caption id="attachment_30542" align="aligncenter" width="1920"]Particle Therapy Market | Exactitude Consultancy
Particle Therapy Market | Exactitude Consultancy
[/caption] The particle therapy market is anticipated to be dominated by a number of regions in 2021 and beyond. With the greatest number of operating particle therapy facilities and the highest rate of treatment uptake, North America dominated the particle therapy market in 2021. There is numerous particle therapy centers that are currently operational in the US, and more are being built. Several regions are anticipated to see significant growth in the particle therapy market in 2021, but Asia Pacific is predicted to grow at the fastest rate. In recent years, the Asia Pacific area has significantly increased the infrastructure for particle therapy, and several new particle therapy facilities are currently being built or developed. The incidence of cancer is notably high in the Asia Pacific area, especially in China and India. This opens up a sizable market for particle therapy procedures, which have benefits over conventional radiation therapy and chemotherapy include higher precision and fewer side effects. With a number of established particle therapy centers and an increasing number under construction, Europe is another key competitor in the market for particle therapy. One of the most active nations in the region for the development of particle therapy is the UK, followed by Germany and Italy.

Key Market Segments: Particle therapy Market

Particle Therapy Market By Type, 2020-2030, (USD Million)
  • Proton Therapy
  • Heavy Ion Therapy
Particle Therapy Market By Product, 2020-2030, (USD Million)
  • Synchrotron
  • Cyclotrons
Particle Therapy Market By Cancer Type, 2020-2030, (USD Million)
  • Prostate Cancer
  • Lung Cancer
  • Pediatric Cancer
  • Breast Cancer
Particle Therapy Market By End User, 2020-2030, (USD Million)
  • Hospitals
  • Research Centers
Particle Therapy Market By Region, 2020-2030, (USD Million)
  • North America
  • Asia Pacific
  • Europe
  • South America
  • Middle East And Africa
Important Countries In All Regions Are Covered.

Exactitude Consultancy Services Key Objectives:

  • Increasing sales and market share
  • Developing new Product
  • Improving profitability
  • Entering new markets
  • Enhancing brand reputation

Key Question Answered

  • What is the expected growth rate of the particle therapy market over the next 7 years?
  • Who are the major players in the particle therapy market and what is their market share?
  • What are the end-user industries driving demand for market and what is their outlook?
  • What are the opportunities for growth in emerging markets such as Asia-Pacific, Middle East, and Africa?
  • How is the economic environment affecting the particle therapy market, including factors such as interest rates, inflation, and exchange rates?
  • What is the expected impact of research centers policies and regulations on the particle therapy market?
  • What is the current and forecasted size and growth rate of the global particle therapy market?
  • What are the key drivers of growth in the particle therapy market?
  • What are the distribution channels and supply chain dynamics in the particle therapy market?
  • What are the technological advancements and innovations in the particle therapy market and their impact on product development and growth?
  • What are the regulatory considerations and their impact on the market?
  • What are the challenges faced by players in the particle therapy market and how are they addressing these challenges?
  • What are the opportunities for growth and expansion in the particle therapy market?
  • What are the product offerings and specifications of leading players in the market?

  1. INTRODUCTION

    1. MARKET DEFINITION

    2. MARKET SEGMENTATION

    3. RESEARCH TIMELINES

    4. ASSUMPTIONS AND LIMITATIONS



  2. RESEARCH METHODOLOGY

    1. DATA MINING

      1. SECONDARY RESEARCH

      2. PRIMARY RESEARCH

      3. SUBJECT-MATTER EXPERTS’ ADVICE



    2. QUALITY CHECKS

      1. FINAL REVIEW



    3. DATA TRIANGULATION

      1. BOTTOM-UP APPROACH

      2. TOP-DOWN APPROACH

      3. RESEARCH FLOW



    4. DATA SOURCES



  3. EXECUTIVE SUMMARY

  4. MARKET OVERVIEW

    1. GLOBAL PARTICLE THERAPY MARKET OUTLOOK

      1. MARKET DRIVERS

      2. MARKET RESTRAINTS

      3. MARKET OPPORTUNITIES



    2. IMPACT OF COVID-19 ON PARTICLE THERAPY MARKET

    3. PORTER’S FIVE FORCES MODEL

      1. THREAT FROM NEW ENTRANTS

      2. THREAT FROM SUBSTITUTES

      3. BARGAINING POWER OF SUPPLIERS

      4. BARGAINING POWER OF CUSTOMERS

      5. DEGREE OF COMPETITION



    4. END USER VALUE CHAIN ANALYSIS



  5. GLOBAL PARTICLE THERAPY MARKET BY TYPE (USD MILLION), 2020-2030

    1. PROTON THERAPY

    2. HEAVY ION THERAPY



  6. GLOBAL PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION), 2020-2030

    1. SYNCHROTRON

    2. CYCLOTRONS



  7. GLOBAL PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION), 2020-2030

    1. PROSTATE CANCER

    2. LUNG CANCER

    3. PEDIATRIC CANCER

    4. BREAST CANCER



  8. GLOBAL PARTICLE THERAPY MARKET BY END USER (USD MILLION), 2020-2030

    1. HOSPITALS

    2. RESEARCH CENTERS



  9. GLOBAL PARTICLE THERAPY MARKET BY REGION (USD MILLION), 2020-2030

    1. NORTH AMERICA

      1. US

      2. CANADA

      3. MEXICO



    2. SOUTH AMERICA

      1. BRAZIL

      2. ARGENTINA

      3. COLOMBIA

      4. REST OF SOUTH AMERICA



    3. EUROPE

      1. GERMANY

      2. UK

      3. FRANCE

      4. ITALY

      5. SPAIN

      6. RUSSIA

      7. REST OF EUROPE



    4. ASIA PACIFIC

      1. INDIA

      2. CHINA

      3. JAPAN

      4. SOUTH KOREA

      5. AUSTRALIA

      6. SOUTH-EAST ASIA

      7. REST OF ASIA PACIFIC



    5. MIDDLE EAST AND AFRICA

      1. UAE

      2. SAUDI ARABIA

      3. SOUTH AFRICA

      4. REST OF MIDDLE EAST AND AFRICA







  1. COMPANY PROFILES*


(BUSINESS OVERVIEW, COMPANY SNAPSHOT, PRODUCTS OFFERED, RECENT DEVELOPMENTS)

  1. IBA WORLDWIDE

  2. MEVION MEDICAL SYSTEMS

  3. VARIAN MEDICAL SYSTEMS

  4. SUMITOMO HEAVY INDUSTRIES LTD

  5. HITACHI LTD

  6. TOSHIBA MEDICAL SYSTEMS CORP.

  7. PROVISION HEALTHCARE LLC.

  8. DANFYSIK A/S

  9. OPTIVUS PROTON THERAPY

  10. PROTOM INTERNATIONAL INC

  11. ADVANCED ONCOLOGY PLC

  12. ION BEAM APPLICATION SA

  13. ELEKTA AB


*THE COMPANY LIST IS INDICATIVE

 LIST OF TABLES

TABLE 1 GLOBAL PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 2 GLOBAL PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 3 GLOBAL PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 4 GLOBAL PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 5 GLOBAL PARTICLE THERAPY MARKET BY REGION (USD MILLION) 2020-2030

TABLE 6 NORTH AMERICA PARTICLE THERAPY MARKET BY COUNTRY (USD MILLION) 2020-2030

TABLE 7 NORTH AMERICA PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 8 NORTH AMERICA PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 9 NORTH AMERICA PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 10 NORTH AMERICA PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 11 US PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 12 US PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 13 US PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 14 US PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 15 CANADA PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 16 CANADA PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 17 CANADA PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 18 CANADA PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 19 MEXICO PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 20 MEXICO PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 21 MEXICO PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 22 MEXICO PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 23 SOUTH AMERICA PARTICLE THERAPY MARKET BY COUNTRY (USD MILLION) 2020-2030

TABLE 24 SOUTH AMERICA PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 25 SOUTH AMERICA PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 26 SOUTH AMERICA PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 27 SOUTH AMERICA PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 28 BRAZIL PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 29 BRAZIL PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 30 BRAZIL PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 31 BRAZIL PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 32 ARGENTINA PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 33 ARGENTINA PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 34 ARGENTINA PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 35 ARGENTINA PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 36 COLOMBIA PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 37 COLOMBIA PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 38 COLOMBIA PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 39 COLOMBIA PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 40 REST OF SOUTH AMERICA PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 41 REST OF SOUTH AMERICA PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 42 REST OF SOUTH AMERICA PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 43 REST OF SOUTH AMERICA PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 44 ASIA-PACIFIC PARTICLE THERAPY MARKET BY COUNTRY (USD MILLION) 2020-2030

TABLE 45 ASIA-PACIFIC PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 46 ASIA-PACIFIC PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 47 ASIA-PACIFIC PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 48 ASIA-PACIFIC PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 49 INDIA PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 50 INDIA PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 51 INDIA PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 52 INDIA PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 53 CHINA PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 54 CHINA PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 55 CHINA PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 56 CHINA PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 57 JAPAN PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 58 JAPAN PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 59 JAPAN PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 60 JAPAN PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 61 SOUTH KOREA PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 62 SOUTH KOREA PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 63 SOUTH KOREA PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 64 SOUTH KOREA PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 65 AUSTRALIA PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 66 AUSTRALIA PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 67 AUSTRALIA PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 68 AUSTRALIA PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 69 SOUTH-EAST ASIA PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 70 SOUTH-EAST ASIA PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 71 SOUTH-EAST ASIA PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 72 SOUTH-EAST ASIA PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 73 REST OF ASIA PACIFIC PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 74 REST OF ASIA PACIFIC PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 75 REST OF ASIA PACIFIC PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 76 REST OF ASIA PACIFIC PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 77 EUROPE PARTICLE THERAPY MARKET BY COUNTRY (USD MILLION) 2020-2030

TABLE 78 EUROPE PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 79 EUROPE PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 80 EUROPE PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 81 EUROPE PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 82 GERMANY PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 83 GERMANY PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 84 GERMANY PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 85 GERMANY PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 86 UK PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 87 UK PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 88 UK PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 89 UK PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 90 FRANCE PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 91 FRANCE PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 92 FRANCE PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 93 FRANCE PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 94 ITALY PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 95 ITALY PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 96 ITALY PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 97 ITALY PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 98 SPAIN PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 99 SPAIN PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 100 SPAIN PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 101 SPAIN PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 102 RUSSIA PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 103 RUSSIA PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 104 RUSSIA PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 105 RUSSIA PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 106 REST OF EUROPE PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 107 REST OF EUROPE PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 108 REST OF EUROPE PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 109 REST OF EUROPE PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 110 MIDDLE EAST AND AFRICA PARTICLE THERAPY MARKET BY COUNTRY (USD MILLION) 2020-2030

TABLE 111 MIDDLE EAST AND AFRICA PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 112 MIDDLE EAST AND AFRICA PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 113 MIDDLE EAST AND AFRICA PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 114 MIDDLE EAST AND AFRICA PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 115 UAE PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 116 UAE PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 117 UAE PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 118 UAE PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 119 SAUDI ARABIA PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 120 SAUDI ARABIA PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 121 SAUDI ARABIA PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 122 SAUDI ARABIA PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 123 SOUTH AFRICA PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 124 SOUTH AFRICA PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 125 SOUTH AFRICA PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 126 SOUTH AFRICA PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

TABLE 127 REST OF MIDDLE EAST AND AFRICA PARTICLE THERAPY MARKET BY TYPE (USD MILLION) 2020-2030

TABLE 128 REST OF MIDDLE EAST AND AFRICA PARTICLE THERAPY MARKET BY PRODUCT (USD MILLION) 2020-2030

TABLE 129 REST OF MIDDLE EAST AND AFRICA PARTICLE THERAPY MARKET BY CANCER TYPE (USD MILLION) 2020-2030

TABLE 130 REST OF MIDDLE EAST AND AFRICA PARTICLE THERAPY MARKET BY END USER (USD MILLION) 2020-2030

LIST OF FIGURES

FIGURE 1 MARKET DYNAMICS

FIGURE 2 REPORT TIMELINES: YEARS CONSIDERED

FIGURE 3 BOTTOM-UP APPROACH

FIGURE 4 RESEARCH FLOW

FIGURE 5 GLOBAL PARTICLE THERAPY MARKET BY TYPE, USD MILLION, 2020-2030

FIGURE 6 GLOBAL PARTICLE THERAPY MARKET BY PRODUCT, USD MILLION, 2020-2030

FIGURE 7 GLOBAL PARTICLE THERAPY MARKET BY CANCER TYPE, USD MILLION, 2020-2030

FIGURE 8 GLOBAL PARTICLE THERAPY MARKET BY END USER, USD MILLION, 2020-2030

FIGURE 9 GLOBAL PARTICLE THERAPY MARKET BY REGION, USD MILLION, 2020-2030

FIGURE 10 PORTER’S FIVE FORCES MODEL

FIGURE 11 GLOBAL PARTICLE THERAPY MARKET BY TYPE, USD MILLION, 2022

FIGURE 12 GLOBAL PARTICLE THERAPY MARKET BY PRODUCT, USD MILLION, 2022

FIGURE 13 GLOBAL PARTICLE THERAPY MARKET BY CANCER TYPE, USD MILLION, 2022

FIGURE 14 GLOBAL PARTICLE THERAPY MARKET BY END USER, USD MILLION, 2022

FIGURE 15 GLOBAL PARTICLE THERAPY MARKET BY REGION, USD MILLION, 2022

FIGURE 16 MARKET SHARE ANALYSIS

FIGURE 17 IBA WORLDWIDE: COMPANY SNAPSHOT

FIGURE 18 MEVION MEDICAL SYSTEMS: COMPANY SNAPSHOT

FIGURE 19 VARIAN MEDICAL SYSTEMS: COMPANY SNAPSHOT

FIGURE 20 SUMITOMO HEAVY INDUSTRIES LTD: COMPANY SNAPSHOT

FIGURE 21 HITACHI LTD: COMPANY SNAPSHOT

FIGURE 22 TOSHIBA MEDICAL SYSTEMS CORP.: COMPANY SNAPSHOT

FIGURE 23 PROVISION HEALTHCARE LLC.: COMPANY SNAPSHOT

FIGURE 24 DANFYSIK A/S: COMPANY SNAPSHOT

FIGURE 25 OPTIVUS PROTON THERAPY: COMPANY SNAPSHOT

FIGURE 26 PROTOM INTERNATIONAL INC: COMPANY SNAPSHOT

FIGURE 27 ADVANCED ONCOLOGY PLC: COMPANY SNAPSHOT

FIGURE 28 ION BEAM APPLICATION SA: COMPANY SNAPSHOT

FIGURE 29 ELEKTA AB: COMPANY SNAPSHOT

DOWNLOAD FREE SAMPLE REPORT

Kindly share your specific requirement (if any)
6807

License Type

Single User

US$ 3499

Multi User

US$ 4499

Corporate User

US$ 5499

Get Sample to Email

SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

WANT TO CUSTOMIZE THE REPORT?

Our Clients Speak

We asked them to research ‘ Equipment market’ all over the world, and their whole arrangement was helpful to us. thehealthanalytics.com insightful analysis and reports contributed to our current analysis and in creating a future strategy. Besides, the te

Yosuke Mitsui

Senior Associate Construction Equipment Sales & Marketing

We asked them to research ‘Equipment market’ all over the world, and their whole arrangement was helpful to us. thehealthanalytics.com insightful analysis and reports contributed to our current analysis and in creating a future strategy. Besides, the te

Yosuke Mitsui

Senior Associate Construction Equipment Sales & Marketing

Why choose us

Proactive

We manage our resources 24/7 to identify issues and address them before they become problems

Quality & Reliability

We are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach

6 Major regions and 40+ countries level analysis accomplished

Competitive Pricing

Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery

In-Depth Database

In-Depth Database

Our Report’s database covers almost all topics of all regions over the Globe.

Recognised Publishing Sources

Recognised Publishing Sources

Tie ups with top publishers around the globe.

Customer Support

Customer Support

Complete pre and post sales support.

Safe & Secure

Safe & Secure

Complete secure payment process.